Embed Size (px)
Citation preview
Scr MMP-1
Supplementary Fig. 1, Ganguly et al.
0
25
50
75
100
Scr MMP-3
ScrMMP-3 MT1-MMP
100m
Rel
ativ
e In
vasi
on
0
25
50
75
100
Scr MMP-1
100m100m100m
a b c
100m100m
Scr
Scr MT1-MMP
50
75
0
25
100R
elat
ive
Inva
sio
n
Rel
ativ
e In
vasi
on
MT1-MMP
Actin
600
200Actin
MMP-3
siRNA: Scr MMP-3
200
400
Actin
MMP-1
200300
siRNA: Scr MMP-1
siRNA: Scr MT1-MMP
Supplementary Fig. 2, Ganguly et al.
Rel
ativ
e M
MP
-1 e
xpre
ssio
n
(MM
P-1
/-A
ctin
)
0
0.25
50
75
100
STI571: - +
STI571: - +
Actin
MMP-1
200
300
GST-Crk GST-STAT3 GST
GST-STAT3
GST-Crk
Ab
l PP
A
rg P
P
Ab
l PP
A
rg P
P
Arg
PP
A
bl P
PIP:
182
26
115
82
64
49
37
GST
Supplementary Fig. 3, Ganguly et al.
Autophosphorylated c-Abl/Arg
GST:
Supplementary Fig. 4, Ganguly et al.
Primers: Abl Arg
siRNA: Scr Abl Arg Scr Abl Arg Scr Abl Arg Scr Abl Arg
Percent of: 100 44 76 100 35 103 100 121 14 100 166 18Scrambled
Actin
GFP GFP-MMP-1 GFP GFP-MMP-1
Abl/Arg
Cell Line:
3 H-T
hym
idin
e In
corp
ora
tio
n
(CP
M X
10 4
)
0
246
810
12
14
Supplementary Fig. 5, Ganguly et al.
Scr STAT3
a
0
10
20
30
40
siRNA: Scr Arg Scr Arg
pcDNA STAT3C
b
Cleavage product
STI571: - + - +pcDNA STAT3C
115
82
Percent of Untreated: 100 437 100 270
c
49
-actin blot
3H
-Th
ymid
ine
Inco
rpo
rati
on
(C
PM
X10
4)
Rel
ativ
e P
AR
P C
leav
age
(PA
RP
/-a
ctin
)
STI571: - + - +
PARP blot
0
100
200
300
400
500
pcDNA STAT3C
Supplementary Fig. 6, Ganguly et al.
PARP blots
STI571: - + - + - +
-actin blot
115
82
37
Treatment/Starvation Time: 48h 96h
Cleavage product
GAPDH blot37
Supplementary Fig. 7, Ganguly et al.
